Summary
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. The Company develops C5 complement inhibitors and apogens which are two classes of potential therapeutic compounds designed to selectively target specific disease-causing segments of the immune system.
Deals Overview
Parent Company
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.
Senior Management
Ludwig N. Hantson
CEO
Marc Dunoyer
CEO
Paul J. Clancy
CFO
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy